This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
mtaschetta-millane Wed, 07/10/2024 - 09:02 July 10, 2024 — CellProthera , a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. , The ProtheraCytes, which are autologous, expanded CD34+ stem cells, were well tolerated with no unexpected serious adverse events reported.
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heartattack. The study enrolled 6,522 people treated for acute myocardialinfarction at 451 centers in 22 countries. About 32% had Type 2 diabetes.
milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heartattack or stroke within three months of a prior heartattack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.
The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heartattack or stroke within three months of a prior heartattack, according to research presented at ACC.24, 24, the American College of Cardiology Annual Annual Scientific Session.
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heartattack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heartattacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect.
The findings call into question the routine use of beta blockers for all patients following a heartattack, which have stood as a mainstay of care for decades. Approximately 50% of heartattack survivors do not experience heart failure. Over a median follow-up period of 3.5
The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardialinfarction (STEMI), the most severe form of a heartattack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), 24), being held April 6-8 in Atltanta, GA.
milla1cf Mon, 04/08/2024 - 18:07 April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heartattack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.
Pocket-Sized Kardia 12L ECG System milla1cf Tue, 06/25/2024 - 18:55 June 25, 2024 — AliveCor , the global leader in AI -powered cardiology, today announced the U.S. This is the world’s first AI that can detect life-threatening cardiac conditions, including heartattacks, using a reduced leadset.
Getty Images milla1cf Thu, 01/25/2024 - 20:44 January 25, 2024 — Agepha Pharma , a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment ( LODOCO – colchicine, 0.5 mg tablets for therapeutic intervention. In June 2023, the U.S.
Using artificial intelligence (AI) to aid clinical decision making in identifying and managing myocardialinfarction (MI; heartattack) in patients presenting to the emergency department (ED) with suspected cardiac conditions does not improve cardiovascular outcomes. 2 Sept.).
Study shows that cardiac spheroids, derived from human induced pluripotent stem cells, can be easily transported and injected into damaged areas of the heart to promote its regeneration and recovery of function. Myocardialinfarctions , commonly known as “heartattacks,” are on the rise, resulting in a significant number of deaths each year.
Cardiovascular disease is the most common cause of death and disability globally, largely driven by myocardialinfarction and ischemic stroke caused by atherosclerosis (plaque build-up in the arteries).
milla1cf Sun, 04/07/2024 - 18:20 April 7, 2024 — An estimated 1 in 5 U.S. adults—and more than 2 in 5 adults aged 60 years and older—have elevated triglycerides, also known as hypertriglyceridemia , putting them at an increased risk for heartattacks and stroke.
3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heartattack or myocardialinfarction (MI), stroke, and cardiovascular (CV) death.4 milligrams per liter (mg/L) are linked to increased risk of heartattacks or risk of a repeat heartattack.23
milla1cf Thu, 03/21/2024 - 11:08 March 21, 2024 — The U.S. Food and Drug Administration ( FDA ) announced that Abiomed is recalling the Instructions for Use for its Impella Left Sided Blood Pumps because the pump catheter may perforate (cut) the wall of the left ventricle in the heart.
The impact of this narrowing can ultimately result in angina (chest pain), which has been shown to double the risk of major cardiovascular events,1 as well as myocardialinfarction ( heartattack ) or even death. Use Heart to Act on Angina. Accessed May 2024. Available at: [link].
Heart disease remains the leading cause of death for men and women. 80% of heartattacks and strokes linked to CVD are preventable with optimal risk factor management. However, every 40 seconds, an individual in the US suffers a heartattack. What are we falling short?
milla1cf Wed, 03/13/2024 - 16:52 March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.
tim.hodson Tue, 10/15/2024 - 12:12 Oct. 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ image analysis software, beginning Nov.
tim.hodson Tue, 09/24/2024 - 15:46 Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Following promising Phase II results from the DUMAS trial in stroke patients in the Netherlands, we’re now advancing to a Phase II trial in the UK for myocardialinfarction following MHRA approval.
Stroke, Volume 55, Issue Suppl_1 , Page AWP64-AWP64, February 1, 2024. Introduction:While timely therapy of neurologic and cardiac emergencies can improve outcomes, patients often fail to identify acute events resulting in delays in seeking emergency care.
He reported a history of “Wolf-Parkinson-White” and “heartattack” but said neither had been treated. AIVR is not always the result of significant pathology, but is classically associated with the reperfusion phase of acute myocardialinfarction. Am Heart J 1999;137:799–805. Do not treat AIVR.
An Overnight Sensation (a century in the making) Efforts to measure the electrical activity of the heart had been well underway since the late 19th Century, though it was the Dutch physiologist Willem Einthoven, improving on these prior developments, who created what we recognize as the ECG.
tim.hodson Tue, 10/01/2024 - 10:50 PHOTO CAPTION: The Elucid PlaqueIQ user interface is a fully interactive visualization of the patient’s coronary anatomy, showing specific plaque type and amount across various views to inform physician assessment of risk and patient-specific treatment pathway.
Getty Images milla1cf Mon, 04/29/2024 - 13:06 April 29, 2024 — Women with heart disease are less often treated with cholesterol-lowering drugs than men, according to research presented today at ESC Preventive Cardiology 2024 , a scientific congress of the European Society of Cardiology ( ESC ).1 Eur Heart J.
A recent systematic review and meta-analysis examined a range of commonly used supplements and whether they improved cardiovascular risk factors like blood pressure and cardiovascular events such as heartattacks and stroke. Heartattacks (Myocardialinfarctions) were reduced by 15%, and coronary artery disease was reduced by 14%.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content